Chemotherapy-induced
nausea and
vomiting(CINV)is one of the side effects causing significant psychological and
physical suffering in patients receiving
chemotherapy. Because CINV often impairs patients' quality of life and leads to discontinuation of treatments,
antiemetic therapy has been considered important. The MASCC Antiemesis Tool(MAT)was proposed for the assessment of acute and delayed
nausea and
vomiting after, we evaluated the actual situation of
nausea and
vomiting for Japanese patients. In a previous investigation, even conventional antiemesis
therapy was a highly effective treatment during the acute phase, but the control of
nausea and
vomiting during the delayed phase proved difficult. Recently, a new5 -HT3 receptor blocker(
palonosetron)and an NK1 receptor blocker(
aprepitant) were introduced, and an effective treatment of
nausea and
vomiting for the delayed phase is non expected. In this examination, we evaluated the usefulness of the new
antiemetic drugs(
palonosetron and
aprepitant)in 12 prospective patients with
breast cancer(40-69 years old, median age 53 years old)for whom FEC
therapy was given as an ambulant treatment using MAT. No
vomiting occurred in the acute and delayed phase.
Nausea during the acute phase was controlled, and was mild during the delayed phase, also. It was confirmed that the onset of acute and delayed
nausea and
vomiting were relieved by the newantiemetic agents compared with the previous MAT evaluation.